GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) reported second-quarter 2026 results that came in close to Wall Street's forecasts, and shares moved up about 4% in after-hours trading as investors weighed softer overall sales against faster growth in subscriptions and pharma manufacturer solutions.
Revenue and EPS versus expectations
GoodRx generated $200.4 million in revenue for the quarter, compared with the consensus estimate of approximately $197.0 million. Non-GAAP EPS was $0.08, versus the $0.0808 analysts were expecting. Both figures fall within roughly 2% of estimates, so the quarter is best characterized as in line with expectations rather than a decisive outperformance or shortfall.
What drove the quarter
Revenue declined 1% year over year, as growth in newer streams did not fully offset pressure in the core prescription transactions business. Prescription transactions revenue fell 26% to $106.4 million, which management attributed to retail pharmacy store closures, lower volume in one integrated savings program, and a deliberate shift of product and marketing investment toward subscriptions.
The brighter spots were in the company's expansion areas. Subscription revenue rose 39% to $28.5 million, supported by condition-specific programs, particularly weight loss. Pharma Direct revenue jumped 76% to $61.6 million, helped by GLP-1 access programs. Those segments helped keep overall profitability stable, with adjusted EBITDA margin at 31.8%.
Key Q2 metrics
- Total revenue: $200.4 million, down 1% year over year
- Net income: $8.5 million, margin 4.3%
- Adjusted EBITDA: $63.7 million, margin 31.8%
- Net cash provided by operating activities: $80.8 million
- Subscription plans: 764,000, up from 668,000 a year earlier
- Monthly Active Consumers: 5.0 million, down from 6.4 million a year earlier
The decline in Monthly Active Consumers reflects the broader retail pharmacy environment and the company's decision to favor subscription-based engagement. Management also noted lower near-term unit economics in prescription transactions, a trade-off it says is designed to support long-term durability.
Guidance and outlook
Management raised its full-year 2026 revenue guidance to $790 million to $805 million, with adjusted EBITDA of $240 million to $250 million. The revenue range brackets the analyst consensus of roughly $791.3 million and sits above it at the midpoint, which may help explain the positive after-hours reaction. The company did not provide specific Q3 guidance.
Bottom line
Investors appear to be focusing on the reacceleration in subscription and Pharma Direct revenue, as well as stronger operating cash flow, rather than the overall decline in sales. The main risks remain the retail pharmacy landscape, lower near-term unit economics, and competition in the medication savings space.
To see how prior quarterly results compare, readers can review GoodRx's historical earnings data. For updated consensus estimates and forward projections, view the latest forecast page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
GoodRx (NASDAQ:GDRX) Q2 2026: Subscription and Pharma Direct Growth Lift Shares Despite Revenue Decline
GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) reported second-quarter 2026 results that came in close to Wall Street's forecasts, and shares moved up about 4% in after-hours trading as investors weighed softer overall sales against faster growth in subscriptions and pharma manufacturer solutions.
Revenue and EPS versus expectations
GoodRx generated $200.4 million in revenue for the quarter, compared with the consensus estimate of approximately $197.0 million. Non-GAAP EPS was $0.08, versus the $0.0808 analysts were expecting. Both figures fall within roughly 2% of estimates, so the quarter is best characterized as in line with expectations rather than a decisive outperformance or shortfall.
What drove the quarter
Revenue declined 1% year over year, as growth in newer streams did not fully offset pressure in the core prescription transactions business. Prescription transactions revenue fell 26% to $106.4 million, which management attributed to retail pharmacy store closures, lower volume in one integrated savings program, and a deliberate shift of product and marketing investment toward subscriptions.
The brighter spots were in the company's expansion areas. Subscription revenue rose 39% to $28.5 million, supported by condition-specific programs, particularly weight loss. Pharma Direct revenue jumped 76% to $61.6 million, helped by GLP-1 access programs. Those segments helped keep overall profitability stable, with adjusted EBITDA margin at 31.8%.
Key Q2 metrics
The decline in Monthly Active Consumers reflects the broader retail pharmacy environment and the company's decision to favor subscription-based engagement. Management also noted lower near-term unit economics in prescription transactions, a trade-off it says is designed to support long-term durability.
Guidance and outlook
Management raised its full-year 2026 revenue guidance to $790 million to $805 million, with adjusted EBITDA of $240 million to $250 million. The revenue range brackets the analyst consensus of roughly $791.3 million and sits above it at the midpoint, which may help explain the positive after-hours reaction. The company did not provide specific Q3 guidance.
Bottom line
Investors appear to be focusing on the reacceleration in subscription and Pharma Direct revenue, as well as stronger operating cash flow, rather than the overall decline in sales. The main risks remain the retail pharmacy landscape, lower near-term unit economics, and competition in the medication savings space.
To see how prior quarterly results compare, readers can review GoodRx's historical earnings data. For updated consensus estimates and forward projections, view the latest forecast page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »